The Bradford Era

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA ® (infliximab-dyyb) Findings reinforce clinic...

JERSEY CITY, N.J. , March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA...

JERSEY CITY, N.J. , March 9, 2025 /PRNewswire/ -- Celltrion today announcedthe U.S. Food and Drug Administration (FDA) approved OMLYCLO ® ( omalizumab...

JERSEY CITY, N.J. , March 3, 2025 /PRNewswire/ -- Celltrion today announcedthat the U.S. Food and Drug Administration (FDA) has approved STOBOCLO ® (C...

JERSEY CITY, N.J. , Jan. 30, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA ® (C...

INCHEON, South Korea , Jan. 14, 2025 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its inno...

JERSEY CITY, N.J. , Dec. 17, 2024 /PRNewswire/ -- Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved STEQEYMA ® (...